The latest price target for Greenwich LifeSciences (NASDAQ:GLSI) was reported by HC Wainwright & Co. on May 22, 2024. The analyst firm set a price target for $36.00 expecting GLSI to rise to within 12 months (a possible 108.71% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Greenwich LifeSciences (NASDAQ:GLSI) was provided by HC Wainwright & Co., and Greenwich LifeSciences reiterated their buy rating.

There is no last upgrade for Greenwich LifeSciences

There is no last downgrade for Greenwich LifeSciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Greenwich LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Greenwich LifeSciences was filed on May 22, 2024 so you should expect the next rating to be made available sometime around May 22, 2025.

While ratings are subjective and will change, the latest Greenwich LifeSciences (GLSI) rating was a reiterated with a price target of $36.00 to $36.00. The current price Greenwich LifeSciences (GLSI) is trading at is $17.25, which is out of the analyst’s predicted range.